Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Buil
Post# of 62
(Total Views: 372)
Posted On: 02/28/2019 4:48:34 PM
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Building Health and Wellness Profile by Prioritizing Skin Care
- Cosmeceutical industry forecasts anticipate $73 billion market for cosmetic skin care products utilizing active chemical ingredients by 2023
- Therma Bright is using trademarked infrared head technologies to target skin viruses and establish a protective barrier for the human body’s largest organ
- Company is also exploring cannabidiol’s properties as augmenting agent for thermal technologies in fighting pain
Far from being mere tissue, skin is the human body’s largest and fastest-growing organ and a vital protection against harm to all of the body’s other organs and the systems that regulate their function (http://nnw.fm/Iy3yN), which provides an obvious reason for trying to keep skin healthy. Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is focusing its business mission on the development of innovative technologies that strengthen and sustain the body’s outer layer and help people to live healthier lives as a result.
The key to Therma Bright’s vision of enhancing health and wellness is to employ trademarked infrared heat technology against agents that attack the skin, such as insect stings, bites and viruses. The company’s TherOZap technology is a first-generation medical device approved by the U.S. Food and Drug Administration (“FDA”) for the relief of the symptoms of skin pain, itch and inflammation, but Therma Bright has been working on a corollary product that may establish a barrier against stinging and biting insects to combat the Zika virus and other mosquito-borne diseases such as dengue.
Therma Bright is testing final prototypes of the technology against the Zika virus at a research laboratory in a process that’s expected to take several months (http://nnw.fm/46uM0). Initial pre-clinical test results announced last year, when the company was named Jenex, indicated that Toronto, Canada’s Techna Institute had found TherOZap effective for the inactivation of live Zika virus in culture media and the inhibition of Zika virus infection into cultured cells in vitro, according to a company news release (http://nnw.fm/4hgIM).
Those findings led Robert A. Poggie, a regulatory consultant for the FDA, to declare, “Pre-clinical testing of the TherOZap technology indicates effectiveness in inhibiting Zika virus, which holds promise for the US FDA accepting marketing claims and associated data via 510(k) review,” according to the news release.
A second trademarked Therma Bright technology, InterceptCS, has also received some regulatory recognition for the treatment of cold sores by killing cells infected with the herpes simplex Type 1 virus. Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome” by Health Canada. The InterceptCS technology is not, however, approved by the United States’ FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease at this time.
InterceptCS delivers controlled topical heat with no risk of burning the skin as it targets the cold sore virus-infected cells. The company’s technologies are representative of a broader cosmeceutical industry that produces products with cosmetic applications of active potential chemical ingredients.
Industry forecasts anticipate a growing worldwide market for cosmeceuticals, with one prediction forecasting growth at a CAGR of 8.21 percent between 2017 and 2023, when the market is expected to reach about $73 billion (http://nnw.fm/k91bY).
Therma Bright is also turning to the positive word of mouth surrounding cannabidiol (“CBD”) for testing the cannabis plant-derived active ingredient in concert with the company’s thermal products as a means of enhancing pain relief therapies (http://nnw.fm/f3NwK).
For more information, visit the company’s website at www.ThermaBright.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Cosmeceutical industry forecasts anticipate $73 billion market for cosmetic skin care products utilizing active chemical ingredients by 2023
- Therma Bright is using trademarked infrared head technologies to target skin viruses and establish a protective barrier for the human body’s largest organ
- Company is also exploring cannabidiol’s properties as augmenting agent for thermal technologies in fighting pain
Far from being mere tissue, skin is the human body’s largest and fastest-growing organ and a vital protection against harm to all of the body’s other organs and the systems that regulate their function (http://nnw.fm/Iy3yN), which provides an obvious reason for trying to keep skin healthy. Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is focusing its business mission on the development of innovative technologies that strengthen and sustain the body’s outer layer and help people to live healthier lives as a result.
The key to Therma Bright’s vision of enhancing health and wellness is to employ trademarked infrared heat technology against agents that attack the skin, such as insect stings, bites and viruses. The company’s TherOZap technology is a first-generation medical device approved by the U.S. Food and Drug Administration (“FDA”) for the relief of the symptoms of skin pain, itch and inflammation, but Therma Bright has been working on a corollary product that may establish a barrier against stinging and biting insects to combat the Zika virus and other mosquito-borne diseases such as dengue.
Therma Bright is testing final prototypes of the technology against the Zika virus at a research laboratory in a process that’s expected to take several months (http://nnw.fm/46uM0). Initial pre-clinical test results announced last year, when the company was named Jenex, indicated that Toronto, Canada’s Techna Institute had found TherOZap effective for the inactivation of live Zika virus in culture media and the inhibition of Zika virus infection into cultured cells in vitro, according to a company news release (http://nnw.fm/4hgIM).
Those findings led Robert A. Poggie, a regulatory consultant for the FDA, to declare, “Pre-clinical testing of the TherOZap technology indicates effectiveness in inhibiting Zika virus, which holds promise for the US FDA accepting marketing claims and associated data via 510(k) review,” according to the news release.
A second trademarked Therma Bright technology, InterceptCS, has also received some regulatory recognition for the treatment of cold sores by killing cells infected with the herpes simplex Type 1 virus. Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome” by Health Canada. The InterceptCS technology is not, however, approved by the United States’ FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease at this time.
InterceptCS delivers controlled topical heat with no risk of burning the skin as it targets the cold sore virus-infected cells. The company’s technologies are representative of a broader cosmeceutical industry that produces products with cosmetic applications of active potential chemical ingredients.
Industry forecasts anticipate a growing worldwide market for cosmeceuticals, with one prediction forecasting growth at a CAGR of 8.21 percent between 2017 and 2023, when the market is expected to reach about $73 billion (http://nnw.fm/k91bY).
Therma Bright is also turning to the positive word of mouth surrounding cannabidiol (“CBD”) for testing the cannabis plant-derived active ingredient in concert with the company’s thermal products as a means of enhancing pain relief therapies (http://nnw.fm/f3NwK).
For more information, visit the company’s website at www.ThermaBright.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)